Rixubis Market Report 2026

Rixubis Market Overview

• The Rixubis market growth in the historic period has been driven by improvements in hemophilia diagnosis rates, availability of recombinant factor ix therapies • Market expansion is supported by expansion of long-acting clotting factor development, increasing demand for personalized hemophilia management • Growth Driver: Surge In Incidence Of Hemophilia Driving Market Growth Due To Rising Demand For Factor VIII Replacement Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rixubis Market?

Rixubis is a recombinant factor IX therapy developed for the treatment and prevention of bleeding episodes in individuals with hemophilia B. It is designed to replace the missing or deficient factor IX in patients, helping to achieve better bleeding control and improved quality of life. The main types of rixubis are recombinant factor IX and plasma-derived factor IX. Recombinant Factor IX is a genetically engineered protein used to treat hemophilia B by replacing the deficient or missing clotting factor IX in the blood. It is used in indications such as routine prophylaxis, treatment of bleeding episodes, and peri-operative management, supporting both hemophilia B treatment and surgical procedures. The users of this treatment include pediatric, adult, and geriatric patients.

What Is The Rixubis Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of long-acting clotting factor development, increasing demand for personalized hemophilia management, growth of home infusion services, advancements in recombinant manufacturing efficiency, rising focus on reduced bleeding episodes. Major trends in the forecast period include increasing adoption of recombinant clotting factors, rising focus on prophylactic hemophilia care, expansion of home-based infusion therapies, improved treatment adherence programs, growing emphasis on patient quality of life.

Global Rixubis Market Segmentation

1) By Type: Recombinant Factor IX, Plasma-derived Factor IX 2) By Indication: Routine Prophylaxis, Treatment Of Bleeding Episodes, Peri-Operative Management 3) By Application: Hemophilia B Treatment, Surgical Procedures 4) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Rixubis Market?

The increasing incidence of hemophilia is expected to drive the growth of the rixubis market going forward. Hemophilia is a genetic bleeding disorder that affects the blood’s ability to clot, leading to prolonged bleeding episodes. Hemophilia is increasing due to advancements in diagnostic techniques, improved awareness, and population growth, leading to the identification of more cases worldwide. Rixubis helps manage hemophilia by providing a recombinant factor IX therapy that aids in preventing and controlling bleeding episodes, enabling individuals with hemophilia B to maintain better overall health and reduce the risk of complications associated with clotting deficiencies. For instance, in Aoril 2025, according to Pfizer, a US-based pharmaceutical and biotechnology corporation, in the 2023 and 24 period, the UK haemophilia A and B patient population exceeded 11,800 individuals, underscoring a sizable and clinically significant treated population. Therefore, the increasing incidence of hemophilia is driving the growth of the rixubis industry. The growing number of clinical trials is expected to propel the growth of the rixubis market going forward. Clinical trials refer to structured research studies conducted to evaluate the effectiveness, safety, and potential side effects of medical treatments, drugs, or devices in humans. The increasing number of clinical trials reflects the growing complexity of healthcare needs, advancements in science, and the broader scope of medical research. Clinical trials support Rixubis by rigorously evaluating its safety, efficacy, and optimal dosing, generating critical clinical evidence that informs regulatory approvals and guides healthcare providers in delivering effective treatment For instance, in December 2024, according to Association of the British Pharmaceutical Industry, a a UK-based trade organization that represents pharmaceutical manufacturers, the total number of industry-sponsored clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023, reflecting growing R&D activity that supports innovation in patient treatments and generates additional revenue streams for the NHS. Therefore, the rising number of clinical trials is driving the growth of rixubis industry. The increasing amount of healthcare research and development funding is expected to propel the growth of the rixubis market going forward. Research and development (R&D) funding refers to the financial resources allocated for advancing medical research and the development of new healthcare treatments and technologies. The amount of research and development funding is increasing due to factors including rising healthcare demands, technological advancements, and government initiatives. Research and development funding is used to advance the development of rixubis, a treatment for hemophilia B, by supporting clinical trials and enhancing therapeutic options for patients. For instance, in May 2023, according to the Congressional Research Service, a US-based government agency, research and development funding is projected to reach $209.7 billion in FY2024, reflecting an increase of $8.9 billion (4.4%) from the estimated $200.8 billion in FY2023. Therefore, the increasing amount of healthcare research and development funding is driving the growth of the rixubis industry.

Key Players In The Global Rixubis Market

Major companies operating in the rixubis market are Takeda Pharmaceutical Company

Regional Insights

North America was the largest region in the rixubis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Rixubis Market?

The rixubis market consists of sales of products such as lyophilized powder and single-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rixubis Market Report 2026?

The rixubis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rixubis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.